AF
SUPN icon

Advisornet Financial’s Supernus Pharmaceuticals SUPN Stock Holding History

Advisornet Financial’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-3
Closed -$90 – 2410
2023
Q2 		$90 Buy
3
+1
+50% +$35 ﹤0.01% 2277
2023
Q1 		$72 Buy
2
+1
+100% +$38 ﹤0.01% 2339
2022
Q4 		$36 Buy
+1
New +$35 ﹤0.01% 2346

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Advisornet Financial's SUPN Position: Q3 2023 in Review

Advisornet Financial sold out of Supernus Pharmaceuticals (SUPN) in Q3 2023, closing a stake of 3 shares — an estimated $90 sold.

Advisornet Financial first reported a position in SUPN in Q4 2022 and held it in 3 quarters. The position peaked at $90 in Q2 2023. 238 funds tracked by Wall St. Rank hold SUPN as of Q3 2023.

  • Advisornet Financial reported no remaining Supernus Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Advisornet Financial sold 3 Supernus Pharmaceuticals shares in Q3 2023, an estimated $90.
  • Advisornet Financial first reported a position in Supernus Pharmaceuticals in Q4 2022 and held it in 3 quarters.
  • Advisornet Financial's Supernus Pharmaceuticals position peaked at $90 in Q2 2023.
  • 238 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2023.

Based on Advisornet Financial's 13F filing for Q3 2023, filed 12 Oct 2023.